NCT03942224View on ClinicalTrials.gov

Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

July 3, 2019

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2026

Conditions
Plasma Cell Myeloma
Interventions
DRUG

Bortezomib

Given SC

BIOLOGICAL

Daratumumab

Given IV

DRUG

Dexamethasone

Given IV and PO

DRUG

Ixazomib

Given PO

Trial Locations (1)

30322

Emory University Hospital/Winship Cancer Institute, Atlanta

Sponsors

Collaborators (1)

Takeda
All Listed Sponsors
collaborator

Takeda

INDUSTRY

collaborator

Janssen, LP

INDUSTRY

collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Cancer Institute (NCI)

NIH

lead

Emory University

OTHER